New learning discoveries about (S)-1-Boc-2-(Hydroxymethyl)piperazine

1030377-21-9, As the paragraph descriping shows that 1030377-21-9 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1030377-21-9,(S)-1-Boc-2-(Hydroxymethyl)piperazine,as a common compound, the synthetic route is as follows.

A mixture of (S)-tert-butyl 2-(hydroxymethyl)piperazine-l -carboxylate (602.7 mg, 2.79 mmol) and (S)-2-methoxyoxirane (308.9 mg, 3.4 mmol) in ethanol (10 mL) was heated at 120 C for 30 min using microwave. The mixture was concentrated to dryness. The residue was purified with flash column chromatography on silica gel using 1 -10% methanol in dichloromethane to afford a oil as the product (794.6 mg) in 94% yield. NMR (500 MHz, Chloroform-*/) delta 4.11 (br, 1H), 3.93 – 3.80 (m, 2H), 3.41 (dd, J = 9.7, 3.7 Hz, 1H), 3.36 (s, 3H), 3.33 (dd, J = 9.7, 6.0 Hz, lH), 3.25 (br, 2H), 3.06 (d, J = 1 1.6 Hz, 1H), 2.89 (br, 2H), 2.79 (d, J = 1 1.2 Hz, 1H), 2.47 (dd, J = 12.7, 9.1 Hz, 1H), 2.49 – 2.33 (m, 1 H), 2.30 – 2.21 (m, 2H), 1.43 (s, 9H). MS for C,4H28N205: 305.2 (MH+).

1030377-21-9, As the paragraph descriping shows that 1030377-21-9 is playing an increasingly important role.

Reference£º
Patent; NEKTAR THERAPEUTICS (INDIA) PVT. LTD.; NEKTAR THERAPEUTICS; SHARMA, PANKAJ; KHATRI, VIJAY KUMAR; GU, XUYUAN; SONG, YUAN; SHEN, MICHAEL LIXIN; SAUTHIER, JENNIFER RIGGS; ANAND, NEEL K.; KOZLOWSKI, ANTONI; ODINECS, ALEKSANDRS; RILEY, TIMOTHY A.; REN, ZHONGXU; MU. YONGQI; SHEN, XIAOMING; YUAN. XUEJUN; AURRECOECHEA, NATALIA; O’MAHONY, DONOGH JOHN ROGER; WO2015/92819; (2015); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Analyzing the synthesis route of 169448-17-3

As the paragraph descriping shows that 169448-17-3 is playing an increasingly important role.

169448-17-3, (S)-tert-Butyl 2-(2-hydroxyethyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Tert-butyl-dimethyl-silyl chloride (3.62 g, 24.02 mmol) and imidazole (3.27 g, 48.03 mmol) were added to a solution of the compound of step 2 (4.609 g, 20.01 mmol) in 75 ml of DCM and the resulting solution was stirred at room temperature for 3 h. The mixture was washed with 50 ml of water and then 50 ml of brine. The aqueous phase was extracted once with DCM. The combined organic phases were dried over sodium sulfate, filtered and evaporated under reduced pressure to give 6.90 g of the title compound as a pale yellow oil., 169448-17-3

As the paragraph descriping shows that 169448-17-3 is playing an increasingly important role.

Reference£º
Patent; SANOFI-AVENTIS; STEINHAGEN, Henning; SCHEIPER, Bodo; MATTER, Hans; MCCORT, Gary; BEGIS, Guillaume; GOBERVILLE, Pascale; THIERS, Berangere; WO2011/12538; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Some tips on tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate

112257-12-2, 112257-12-2 tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate 15829155, apiperazines compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.112257-12-2,tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

4-(2-Oxo-2-piperazin-1-ylethyl)morpholine (42-2) Morpholine (0.22 g, 2.59 mmol), 42-1 (0.61 g, 1.99 mmol) and DIEA (0.33 g, 2.59 mmol) were dissolved in DMF (2 mL) and stirred for 18 hours at room temperature. The DMF was then removed under reduced pressure and the residue partitioned between water and methylene chloride. The methylene chloride was drawn off, dried and evaporated to a solid to afford 42-2. This recovered product was treated with neat trifluoroacetic acid and the excess trifluoroacetic acid evaporated off. The resulting residue was partitioned between methylene chloride and aqueous Na2CO3. The free base did not extract from the aqueous so the aqueous was evaporated to dryness, washed the methanol, and the solids filtered off to afford 42-2. 1H-NMR(CD3O): 3.69(t, 4H); 3.59 (t, 2H); 3.54(t, 2H); 3.22(s, 2H); 2.83(t, 2H); 2.77(t, 2H); 2.49(t, 4H).

112257-12-2, 112257-12-2 tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate 15829155, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Bilodeau, Mark T.; Hartman, George D.; Hoffman JR., Jacob M.; Sisko, John T.; Manley, Peter J.; Smith, Anthony M.; Tucker, Thomas J.; Lumma JR., William C.; Rodman, Leonard; US2002/137755; (2002); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Some tips on 1-Cyclopropylpiperazine

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

The title compound (pale beige solid, 26.5 mg, 40%) was prepared by a procedure similar to Example 400 using (S)-2-methyl-4-(5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pyridin-2-yl)mo holine (50 mg, 80% purity, 0.16 mmol) and N-(5-bromo-4-fluoro-2-((3S,5R)-3,4,5-trimethylpiperazin-l-yl)phenyl)-6-oxo-4- (trifluoromethyl)-l,6-dihydropyridine-3-carboxamide (50.5 mg, 0.1 mmol). 1H NMR (500MHz, METHANOL-d4) delta = 8.32 (s, 1H), 7.97 (s, 1H), 7.92 (br d, J=8.4 Hz, 1H), 7.79 (br d, J=8.8 Hz, 1H), 7.07 (d, J=12.1 Hz, 1H), 6.95 – 6.90 (m, 2H), 4.16 (br d, J=12.7 Hz, 1H), 4.10 – 3.99 (m, 2H), 3.75 – 3.66 (m, 2H), 3.07 (br d, J=10.5 Hz, 2H), 2.96 (dt, J=3.4, 12.3 Hz, 1H), 2.70 – 2.56 (m, 5H), 2.41 (s, 3H), 1.26 (d, J=6.2 Hz, 3H), 1.19 (d, J=5.7 Hz, 6H); LCMS [M + H]+ 603.6.

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference£º
Patent; ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR); AL-AWAR, Rima; ZEPEDA-VELAZQUEZ, Carlos Armando; PODA, Gennady; ISAAC, Methvin; UEHLING, David; WILSON, Brian; JOSEPH, Babu; LIU, Yong; SUBRAMANIAN, Pandiaraju; MAMAI, Ahmed; PRAKESCH, Michael; STILLE, Julia Kathleen; (1053 pag.)WO2017/147700; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Some tips on tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate

154590-34-8, 154590-34-8 tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate 16203508, apiperazines compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.154590-34-8,tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

3-4-2: Preparation of [3-fluoro-4-(BOC-piperazino)]aniline To 150 ml of ethyl acetate were sequentially added 9.3 g (28.6 mmol) of [3-fluoro-4-(BOC-piperazino)]nitrobenzene synthesized in Preparation Example 3-4-1 and 930 mg (10 W %) of Pd/C, followed by reaction in a hydrogen reactor under hydrogen pressure of 4 bar for 6 hours. After the reaction was complete, Pd/C was filtered through celite. The filtrate was distilled under reduced pressure and dried under vacuum at about 40 to afford 8.22 g (yield: 97%) of the desired compound. Mass (M+): 296.1 1H-NMR (DMSO-d6): 1.42(s, 9H), 2.76(brm, 4H), 3.43(brm, 4H), 5.02(s, 2H), 6.33(m, 2H), 6.79(m, 1H).

154590-34-8, 154590-34-8 tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate 16203508, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Ryu, Jei Man; Lee, Jin Soo; Park, Whui Jung; Hwang, Yun Ha; Kim, Ki Yoon; US2011/306606; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Simple exploration of 1-Boc-3,3-Dimethylpiperazine

259808-67-8, As the paragraph descriping shows that 259808-67-8 is playing an increasingly important role.

259808-67-8, 1-Boc-3,3-Dimethylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

tert-butyl 3,3-dimethylpiperazine-1-carboxylate (19.90 g, 92.86 mmol) and (2,2-dimethylpiperazin-1-yl)methanone hydrochloride (Intermediate II) (27.87 g, 84.60 mmol) were dissolved in DMF (300 mL) before HATU (35.45 g, 93.23 mmol) and DIPEA (27.72 g, 37.36 mL, 214.5 mmol) were added. The solution was stirred at room temperature for 3h, and then water was added dropwise. The aq. phase was extracted three times with EtOAc. The combined organic phase was washed with water and brine. The organic phase was then dried over Na2SO4, filtered and the filtrate evaporated under reduced pressure. The crude product was purified passing through a pad of silica gel (25%-33% EtOAc/hexanes affording the title product (34.28 g, 91% yield) as a yellow orange foamy solid, which was used directly in the next step. 1H NMR (400 MHz, Chloroform-d) 7.34 (s, 1H), 7.06 (s, 1H), 3.84 (dd, J = 6.6, 4.8 Hz, 2H), 3.67 – 3.45 (m, 4H), 2.71 (tt, J = 10.3, 5.5 Hz, 1H), 1.85 – 1.77 (m, 4H), 1.77 – 1.71 (m, 1H), 1.57 – 1.51 (m, 2H), 1.49 (s, 9H), 1.49 (s, 9H), 1.43 – 1.31 (m, 3H), 1.01 (s, 3H), 0.97 (s, 3H). ESI-MS m/z calc.525.3567, found 526.61 (M+1)+; Retention time: 3.15 minutes using method A

259808-67-8, As the paragraph descriping shows that 259808-67-8 is playing an increasingly important role.

Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; SAYEGH, Camil Elie; STURINO, Claudio; FOURNIER, Pierre-Andre; LACOSTE, Jean-Eric; DIETRICH, Evelyne; MARTEL, Julien; VALLEE, Frederic; (494 pag.)WO2016/154075; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Some tips on 3-(4-Methylpiperazin-1-yl)propan-1-ol

5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.

5317-33-9, 3-(4-Methylpiperazin-1-yl)propan-1-ol is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5317-33-9, 4-Toluenesulphonyl chloride (3.2 g) was added to a stirred mixture of 1-(3-hydroxypropyl)-4-methylpiperazine (2.4 g), triethylamine (4.6 ml) and methylene chloride (60 ml) and the resultant mixture was stirred at ambient temperature for 2 hours. The solution was washed in turn with a saturated aqueous sodium bicarbonate solution and with water and filtered through phase separating paper. The organic filtrate was evaporated to give 3-(4-methylpiperazin-1-yl)propyl 4-toluenesulphonate as an oil which crystallized on standing (3.7 g); Mass Spectrum: M+H+ 313.

5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; AstraZeneca AB; US2004/48881; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 3022-15-9

3022-15-9, The synthetic route of 3022-15-9 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3022-15-9,Piperazine-2-carboxylic acid dihydrochloride,as a common compound, the synthetic route is as follows.

Piperazine-2-carboxyilc acid dihydrochloride (5.00 g, 24.6 mmol) was dissolved in H2O (80 mL) and 1,4-dioxane (80 mL), and the solution was brought to pH 11 with 50% aqueous NaOH. A solution of di-tert-butyl dicarbonate (5.36 g, 30.8 mmol) in 1,4-dioxane (40 mL) was added dropwise while maintaining the pH at 11 with 50% aqueous NaOH. After 12 h, the reaction mixture was extracted with Et2O (3 x 125 mL). The aqueous layer was brought to pH 2 with concentrated HCl and was extracted with EtOAc (4 x 100 mL). The aqueous solution was brought to pH 9.5 with 50% aqueous NaOH. Benzyl chloroformate (3.70 mL, 24.6 mmol) was added at 10 0C while maintaining the pH at 9.5 with 50% aqueous NaOH. The solution was allowed to warm to rt. After 2 h, the reaction mixture was extracted with Et2O (2 x 100 mL), brought to pH 1 with concentrated HCl, and extracted with EtOAc (3 x 150 mL). The combined EtOAc extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The thick oil was dissolved in THF (100 mL) and cooled to 00C. Borane-THF complex (1.0 M solution in THF, 75 mL, 75 mmol) was added portionwise. After 1 h, the reaction mixture was heated to 50 0C. After 1 h, the reaction mixture was cooled to rt and quenched carefully with MeOH. After evolution of gas ceased, additional MeOH (100 mL) was added and the reaction mixture was heated to 70 0C for 1 h. Upon cooling to rt, the reaction mixture was concentrated under reduced pressure. Purification by column chomatography (20 to 40% EtOAc in Hexanes gradient) gave 4.52 g (52%) of the title compound. Rf = 0.25 in 50% EtOAc/Hexanes; LC-MS: RT = 9.53 min; [M+Na]+ = 373.1; 2.068 g (22%) of dibenzyl 2-(hydroxymethyl)piperazine-l,4-dicarboxylate was also obtained. Rf = 0.18 in 50% EtOAc/Hexanes; LC-MS: RT = 9.47 min; [M+H]+ = 385.1.

3022-15-9, The synthetic route of 3022-15-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CRITICAL THERAPEUTICS, INC.; WO2007/146066; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

New learning discoveries about 120737-59-9

As the paragraph descriping shows that 120737-59-9 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.120737-59-9,tert-Butyl 3-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Methyl-bromoacetate (3.06g, 20.0 mmol) was added to a stirred solution of 4-Boc-2-methyl- piperazine (2. [0G,] 10.0 mmol), sodium iodide [(0.] [LG.)] and N, N-diisopropylethylamine (3.48 ml, 20 mmol) in DCM (50ml) at ambient temperature under nitrogen. After stirring for 16h the reaction mixture was washed with water [(30ML),] brine [(30ML),] dried and evaporated to dryness under reduced pressure. The residue was purified by chromatography on silica, eluting with 0-8percent [MEOH/DCM] to give 68 as a yellow oil (2.7g). MS-ESI: 273 (M++H). [H NMR (CDC13) 1. 05] (d, 3H), 1.47 (s, 9H), 2.50-2. 85 (m, 4H), 3.03-3. 13 (m, 1H), 3.34 (d, 1H), 3.44 (d, [1H),] 3.70 (s, 3H), 3.71-3. 82 (m, 2H)., 120737-59-9

As the paragraph descriping shows that 120737-59-9 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2004/18480; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 5308-25-8

The synthetic route of 5308-25-8 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5308-25-8,1-Ethylpiperazine,as a common compound, the synthetic route is as follows.

5308-25-8, To a solution of 5-chloro-2-nitroaniline (200 mg,1.16 mmol) in dry DMF (4 mL), K2CO3 (240 mg, 1.74 mmol) and compound47 (172 mg, 1.51 mmol) were added. The reaction mixture was heated to 110C for 12 h. Completion of reaction was observed by TLC (1:4/MeOH:CH2Cl2, Rf 0.70). Thereaction mixture was diluted with EtOAc (30 mL), washed successively with H2O (2¡Á30 mL)and brine (20 mL), then dried over MgSO4. The organic layer was removed under reducedpressure and the residue was purified by flash chromatography (SiO2, 1:19/MeOH:CH2Cl2) toafford compound 52 as a yellow solid (110 g, 38%)

The synthetic route of 5308-25-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Chandrika, Nishad Thamban; Shrestha, Sanjib K.; Ngo, Huy X.; Garneau-Tsodikova, Sylvie; Bioorganic and Medicinal Chemistry; vol. 24; 16; (2016); p. 3680 – 3686;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics